VI
Sponsors
GlaxoSmithKline, fan li
Conditions
Pulmonary Disease, Chronic ObstructiveRectal Cancer
Phase 1
Phase 2
Phase 3
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01957163
Start: 2013-10-01End: 2014-04-01Updated: 2017-11-09
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
CompletedNCT02119286
Start: 2013-10-31End: 2014-04-30Updated: 2017-03-23